FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312891878> ?p ?o ?g. }

• W4312891878 endingPage "329" @default.
• W4312891878 startingPage "319" @default.
• W4312891878 abstract "Immunotherapy becomes a promising line of treatment for breast cancer (BC) however, its success rate is still limited. Methods: The study was designed to optimize the condition for producing an effective dendritic cell (DCs) based immunotherapy by using DCs and T lymphocytes together with tumor-infiltrating lymphocytes (TILs) and tumor-infiltrating DCs (TIDCs), treated with anti-PD1 and anti-CTLA4 monoclonal antibodies. This mixture of immune cells was co-cultured with autologous breast cancer cells (BCCs) isolated from 26 BC females. Results: There was a significant upregulation of CD86 and CD83 on DCs (P = 0.001 and 0.017, respectively), similarly upregulation of CD8, CD4 and CD103 on T cells (P = 0.031, 0.027, and 0.011, respectively). While there was a significant downregulation of FOXP3 and combined CD25.CD8 expression on regulatory T cells (P = 0.014 for both). Increased CD8/Foxp3 ratio (P < 0.001) was also observed. CD133, CD34 and CD44 were downregulated on BCCs (P = 0.01, 0.021, and 0.015, respectively). There was a significant increase in interferon-γ (IFN-γ, P < 0.001), lactate dehydrogenase (LDH, P = 0.02), and a significant decrease in vascular endothelial growth factor (VEGF, P < 0.001) protein levels. Gene expression of FOXP3 and Programmed cell death ligand 1 (PDL-1) were downregulated in BCCs (P < 0.001, for both), similarly cytotoxic T lymphocyte antigen-4 (CTLA4, P = 0.02), Programmed cell death 1 (PD-1, P < 0.001) and FOXP3 (P < 0.001) were significantly downregulated in T cells. Conclusion: Ex-vivo activation of immune cells (DCs, T cells, TIDCs, and TILs) with immune checkpoint inhibitors could produce a potent and effective BC immunotherapy. However, these data should be validated on an experimental animal model to be transferred to the clinical setting." @default.
• W4312891878 created "2023-01-05" @default.
• W4312891878 creator A5000138333 @default.
• W4312891878 creator A5022848939 @default.
• W4312891878 creator A5033406657 @default.
• W4312891878 creator A5033437525 @default.
• W4312891878 creator A5035575768 @default.
• W4312891878 creator A5049945362 @default.
• W4312891878 creator A5059222041 @default.
• W4312891878 creator A5077423833 @default.
• W4312891878 creator A5084270727 @default.
• W4312891878 creator A5084559973 @default.
• W4312891878 date "2021-01-01" @default.
• W4312891878 modified "2023-10-15" @default.
• W4312891878 title "Biological and molecular studies on specific immune cells treated with checkpoint inhibitors for the thera-personal approach of breast cancer patients (ex-vivo study)" @default.
• W4312891878 cites W191729897 @default.
• W4312891878 cites W1935243645 @default.
• W4312891878 cites W1962147066 @default.
• W4312891878 cites W1973389945 @default.
• W4312891878 cites W1987520066 @default.
• W4312891878 cites W2000092529 @default.
• W4312891878 cites W2003442857 @default.
• W4312891878 cites W2008389446 @default.
• W4312891878 cites W2019798746 @default.
• W4312891878 cites W2044091978 @default.
• W4312891878 cites W2052707632 @default.
• W4312891878 cites W2060672294 @default.
• W4312891878 cites W2066671159 @default.
• W4312891878 cites W2068971398 @default.
• W4312891878 cites W2087215014 @default.
• W4312891878 cites W2097811455 @default.
• W4312891878 cites W2103938232 @default.
• W4312891878 cites W2107277218 @default.
• W4312891878 cites W2112648444 @default.
• W4312891878 cites W2126932404 @default.
• W4312891878 cites W2128153753 @default.
• W4312891878 cites W2137018390 @default.
• W4312891878 cites W2145302691 @default.
• W4312891878 cites W2145453174 @default.
• W4312891878 cites W2161240454 @default.
• W4312891878 cites W2192080449 @default.
• W4312891878 cites W2204673465 @default.
• W4312891878 cites W2292383635 @default.
• W4312891878 cites W2337944657 @default.
• W4312891878 cites W2344433323 @default.
• W4312891878 cites W2560367415 @default.
• W4312891878 cites W2571686442 @default.
• W4312891878 cites W2574924315 @default.
• W4312891878 cites W2735265951 @default.
• W4312891878 cites W2767343890 @default.
• W4312891878 cites W2774223113 @default.
• W4312891878 cites W2774998201 @default.
• W4312891878 cites W2790131254 @default.
• W4312891878 cites W2799682126 @default.
• W4312891878 cites W2889646458 @default.
• W4312891878 cites W2911100812 @default.
• W4312891878 cites W2971193829 @default.
• W4312891878 cites W2974584278 @default.
• W4312891878 cites W2986663420 @default.
• W4312891878 cites W3006455065 @default.
• W4312891878 cites W3018511607 @default.
• W4312891878 cites W3034113315 @default.
• W4312891878 cites W3181681984 @default.
• W4312891878 cites W4212829041 @default.
• W4312891878 doi "https://doi.org/10.32604/or.2022.025249" @default.
• W4312891878 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37305162" @default.
• W4312891878 hasPublicationYear "2021" @default.
• W4312891878 type Work @default.
• W4312891878 citedByCount "0" @default.
• W4312891878 crossrefType "journal-article" @default.
• W4312891878 hasAuthorship W4312891878A5000138333 @default.
• W4312891878 hasAuthorship W4312891878A5022848939 @default.
• W4312891878 hasAuthorship W4312891878A5033406657 @default.
• W4312891878 hasAuthorship W4312891878A5033437525 @default.
• W4312891878 hasAuthorship W4312891878A5035575768 @default.
• W4312891878 hasAuthorship W4312891878A5049945362 @default.
• W4312891878 hasAuthorship W4312891878A5059222041 @default.
• W4312891878 hasAuthorship W4312891878A5077423833 @default.
• W4312891878 hasAuthorship W4312891878A5084270727 @default.
• W4312891878 hasAuthorship W4312891878A5084559973 @default.
• W4312891878 hasBestOaLocation W43128918781 @default.
• W4312891878 hasConcept C104317684 @default.
• W4312891878 hasConcept C127561419 @default.
• W4312891878 hasConcept C150903083 @default.
• W4312891878 hasConcept C154317977 @default.
• W4312891878 hasConcept C167672396 @default.
• W4312891878 hasConcept C202751555 @default.
• W4312891878 hasConcept C203014093 @default.
• W4312891878 hasConcept C207001950 @default.
• W4312891878 hasConcept C26291073 @default.
• W4312891878 hasConcept C2776090121 @default.
• W4312891878 hasConcept C2777701055 @default.
• W4312891878 hasConcept C2779727006 @default.
• W4312891878 hasConcept C502942594 @default.
• W4312891878 hasConcept C55493867 @default.
• W4312891878 hasConcept C71924100 @default.
• W4312891878 hasConcept C79484868 @default.
• W4312891878 hasConcept C86803240 @default.

• next